Lung Cancer News

Lung, Urothelial Cancers: Phase 1b/2 Trial of Avelumab With Chemotherapy

Lung, Urothelial Cancers: Phase 1b/2 Trial of Avelumab With Chemotherapy

Researchers are evaluating whether avelumab, a PD-L1 inhibitor, is safe and effective in combination with chemotherapy for treating patients with NSCLC or urothelial cancer.

Small-cell Lung Cancer: A Phase 2 Study of p53 Vaccination With Checkpoint Inhibition

Small-cell Lung Cancer: A Phase 2 Study of p53 Vaccination With Checkpoint Inhibition

Researchers are evaluating whether adding a dendritic cell-based p53 vaccine to combination checkpoint inhibition will improve outcomes among patients with recurrent SCLC.

BMI, Age, and Treatment Response May Predict for Survival in Patients With Lung Cancer

BMI, Age, and Treatment Response May Predict for Survival in Patients With Lung Cancer

Researchers retrospectively analyzed the outcomes of 78 patients with stage IV lung SCC who were treated with gemcitabine plus cisplatin as first-line therapy.

Elderly Patients With NSCLC Are Often Undertreated

Elderly Patients With NSCLC Are Often Undertreated

Living in a lower-education area and being African American were associated with not receiving any cancer-directed care.

Proton Therapy May Not Reduce Radiation Exposure in Non-small Cell Lung Cancer

Proton Therapy May Not Reduce Radiation Exposure in Non-small Cell Lung Cancer

PSPT significantly reduced radiation exposure to the heart, but no differences were observed between PSPT and IMRT for the lung or esophagus.

FDA Accepts Supplemental New Drug Application for Osimertinib as First-line Treatment in EGFR-mutant NSCLC

FDA Accepts Supplemental New Drug Application for Osimertinib as First-line Treatment in EGFR-mutant NSCLC

Data from FLAURA may position osimertinib as the first-line standard of care for patients with EGFR-mutant NSCLC.

Phase 2 Trial of SBRT and Gene Therapy Prior to Nivolumab for NSCLC

Phase 2 Trial of SBRT and Gene Therapy Prior to Nivolumab for NSCLC

Researchers are evaluating whether patients with metastatic NSCLC will benefit from stereotactic body radiation and a virally mediated gene therapy prior to nivolumab.

Chemotherapy Followed by Radiotherapy Improves Survival in Negative-margin NSCLC

Chemotherapy Followed by Radiotherapy Improves Survival in Negative-margin NSCLC

Data from previous studies suggest that adjuvant chemotherapy and PORT may improve patient outcomes, but the optimal sequence of administration was previously unestablished.

Phase 1 Study of A Virus-based Gene Therapy for Non-small Cell Lung Cancer

Phase 1 Study of A Virus-based Gene Therapy for Non-small Cell Lung Cancer

Researchers are evaluating whether Ad5-yCD/mutTKSR39rep-ADP, an oncolytic adenovirus, can help to improve outcomes among patients with inoperable stage I/IIA NSCLC.

Surgery May Be Superior to Stereotactic Body Radiation Therapy for Early Stage NSCLC

Surgery May Be Superior to Stereotactic Body Radiation Therapy for Early Stage NSCLC

SBRT provides excellent local control and an adequate safety profile, but there is a lack of data comparing SBRT to resection among patients eligible for surgery.

Phase 1 Study of Pembrolizumab With A Vaccine for Metastatic NSCLC

Phase 1 Study of Pembrolizumab With A Vaccine for Metastatic NSCLC

Researchers are evaluating the safety and efficacy of pembrolizumab in combination with a synthetic long peptide vaccine among patients with non-small cell lung cancer.

Phase 2 Study of Lorlatinib for ROS1- and ALK-mutated NSCLC With CNS Metastasis

Phase 2 Study of Lorlatinib for ROS1- and ALK-mutated NSCLC With CNS Metastasis

Researchers are assessing the safety and efficacy of lorlatinib among patients with ROS1 and ALK mutation-positive NSCLC that has metastasized to the CNS.

Phase 1b Study of Human Fibroblast-based Vaccine for Resectable NSCLC

Phase 1b Study of Human Fibroblast-based Vaccine for Resectable NSCLC

Researchers are evaluating the safety and efficacy of a vaccine for patients with resectable NSCLC.

Phase 2 Study of Neoadjuvant Pembrolizumab With or Without Radiation for NSCLC

Phase 2 Study of Neoadjuvant Pembrolizumab With or Without Radiation for NSCLC

Researchers are assessing the efficacy of neoadjuvant pembrolizumab with or without low-dose SRT among patients with stage I to IIIA NSCLC who plan to undergo surgical resection.

Adjuvant Gefitinib Improves Disease-free Survival Among Patients With NSCLC

Adjuvant Gefitinib Improves Disease-free Survival Among Patients With NSCLC

Researchers enrolled 222 patients with completely resected stage II-IIIA (N1-N2) NSCLC to receive adjuvant gefitinib or cisplatin plus vinorelbine.

NSCLC: Tissue, Rather Than Liquid, Biopsy Recommended for Identifying Resistance Mechanisms

NSCLC: Tissue, Rather Than Liquid, Biopsy Recommended for Identifying Resistance Mechanisms

Researchers evaluated the biopsies and outcomes of 5 patients with an EGFR-activating mutation who were initially treated with a first- or second-generation EGFR-TKI.

Bevacizumab Not Recommended as Adjuvant Therapy in NSCLC

Bevacizumab Not Recommended as Adjuvant Therapy in NSCLC

Investigators randomly assigned 1501 patients with completely resected stage IB to IIIA NSCLC to receive chemotherapy alone or chemotherapy plus bevacizumab.

Liquid Biopsies: An Emerging, Effective, Versatile Monitoring Modality in Lung Cancer

Liquid Biopsies: An Emerging, Effective, Versatile Monitoring Modality in Lung Cancer

In lung cancer, it is critical to evaluate the resistance mechanisms so appropriate treatment can be administered.

First-line Osimertinib for EGFR-mutation Positive NSCLC

First-line Osimertinib for EGFR-mutation Positive NSCLC

The discovery of molecular biomarkers and EGFR mutations have shifted the management of NSCLC from traditional cytotoxic chemotherapies towards precision medicine with TKIs.

FDA Approves Alectinib as First-line Therapy for ALK-positive NSCLC

FDA Approves Alectinib as First-line Therapy for ALK-positive NSCLC

Approval was based on results from ALEX, for which researchers randomly assigned 303 patients with ALK-positive NSCLC not previously treated with systemic therapy to receive alectinib or crizotinib.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs